Description

Empagliflozin Tablets 10mg, marketed under the name Pingxinda, are designed for experimental use in laboratory settings to support studies involving glucose regulation, SGLT2 inhibition, and type 2 diabetes mellitus (T2DM). These tablets inhibit sodium-glucose co-transporter 2 (SGLT2) in renal proximal tubules, resulting in reduced reabsorption of glucose and increased urinary glucose excretion in research models.

Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd., this product is approved under H20234642 and adheres to GMP production standards.

?? For laboratory research use only. Not for human use.

Product Parameters

Mechanism & Research Applications

Empagliflozin is a selective SGLT2 inhibitor. It blocks the reabsorption of glucose in the kidney, leading to increased urinary glucose excretion. In preclinical research, this helps simulate conditions similar to those found in patients with type 2 diabetes.

Research applications include:

• Investigating glucose metabolism pathways

• Studying renal sodium-glucose co-transport inhibition

• Modeling T2DM therapies in vitro or in vivo

• Testing combinatorial therapies with metformin or DPP-4 inhibitors

Observed Effects in Research

• Reduced fasting and postprandial blood glucose in test models

• Increased urinary glucose output

• Weight loss and improved insulin sensitivity in rodents

• Reduced systolic blood pressure markers

• Delayed progression of diabetic kidney disease in long-term studies

Safety & Handling

• Research Grade Only – Not for clinical, diagnostic, or human use

• Storage – Store below 25°C in a dry, light-protected environment

• Handling – Use PPE: gloves, lab coat, eye protection

• Shelf Life – Refer to packaging or Certificate of Analysis

• Disposal – Follow institutional guidelines for chemical disposal

Research Use Disclaimer

This product is intended strictly for laboratory research use only. It is not for human or veterinary use, not a drug, and should only be handled by trained professionals.